MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of many must-buy small cap shares to purchase. On April 7, TD Cowen analyst Joseph Thome initiated protection on MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Purchase score. The analyst cited the corporate’s pipeline of remedies focusing on the central nervous system, or CNS, and neuropsychiatric situations.
Thome’s bullish thesis is constructed round ML-007C-MA, which is MapLight’s lead drug candidate designed to enhance on the profile of Cobenfy. Cobenfy is a Bristol Myers Squibb (NYSE:BMY) product used for adults with schizophrenia. ML-007C-MA is a Cobenfy competitor and MapLight intends it to work similar to the latter however with improved comfort.
MapLight’s drug targets the identical M1/M4 receptor mechanism as Cobenfy however with higher tolerability, security, or dosing frequency, in accordance with the corporate. The corporate initiated the drug’s Section 2 trial on September 17, 2025, and expects the info to be out in Q3 2026. MapLight can also be operating a Section 2 examine of ML-007C-MA in Alzheimer’s psychosis, a sign that, if profitable, would considerably develop the drug’s addressable market past schizophrenia. A second pipeline asset, ML-004, is in a Section 2 examine for autism spectrum dysfunction, or ASD, whose knowledge can also be anticipated in Q3 2026. Thome famous that the inventory is undervalued primarily based on the schizophrenia alternative alone.
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is a clinical-stage biotechnology firm. It develops therapies for central nervous system problems, together with schizophrenia, Alzheimer’s illness psychosis, autism spectrum dysfunction, and Parkinson’s illness. Its pipeline consists of a number of drug candidates comparable to ML-007C-MA and ML-004.
Whereas we acknowledge the potential of MPLT as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back threat. In case you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: David Abrams’ Hedge Fund Is Betting On These 8 Shares and 10 Finest Power Storage Shares to Purchase Based on Hedge Funds.
Disclosure: None. Comply with Insider Monkey on Google Information.